# US 2013/0259875 A1 · Acth for treatment of amyotrophic lateral sclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0259875 A1
- Document ID: US20130259875A1
- Status: Published application
- Kind: A1
- Application number: 13/695,602
- Filed: 2011-05-10
- Published: 2013-10-03
- Earliest claimed: 2010-05-11
- Assignees: Questcor Pharmaceuticals, Inc.
- Inventors: Kathleen C. Somera-Molina
- Web page: https://patentgrep.com/patent/US20130259875A1

## CPC

- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/35: Corticotropin [ACTH]
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods of treatment of Amyotrophic Lateral Sclerosis comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.

## Claims

### Claim 1

A method of treating an individual diagnosed with, suspected of having, or predisposed to Amyotrophic Lateral Sclerosis (ALS), comprising administration of adrenocorticotropic hormone (ACTH) peptide, or fragment, analog, complex or aggregate thereof, or any combination thereof, to the individual in need thereof, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered as a first dose and one or more subsequent doses.

### Claim 2 (depends on 1)

The method of claim 1, wherein the ALS is sporadic ALS, or familial type ALS.

### Claim 3 (depends on 1)

The method of claim 1, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered in early stage ALS upon onset of muscle weakness in the limbs and/or slurred and nasal speech.

### Claim 4 (depends on 1)

The method of claim 1, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered upon detection of a mutation in the SOD1 gene.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first dose of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, comprises a dose between about 10 IU and about 150 IU, and the one or more subsequent doses of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered about every day, about every 2 days, about every 5 days, about every week, about every two weeks, about every three weeks, about every month, about every two months, or any combination thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the first dose of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, comprises a dose between about 10 IU and about 150 IU, and the one or more subsequent doses of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are between about 20%-80% of the first dose.

### Claim 7 (depends on 1)

The method of claim 1, wherein the doses of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are administered every 2 days.

### Claim 8 (depends on 1)

The method of claim 1, wherein the doses of ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, are administered every 7 days.

### Claim 9 (depends on 1)

The method of claim 1, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH1-39 peptide having the formula:
(SEQ ID NO: 1)
H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-
1 2 3 4 5 6 7 8 9 10
Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-
11 12 13 14 15 16 17 18 19 20
Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Gln-
21 22 23 24 25 26 27 28 29 30
Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH
31 32 33 34 35 36 37 38 39
or a fragment, complex, aggregate, or analog thereof, or any combination thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a ACTH1-13 peptide (alpha-MSH) having the formula:
(SEQ ID NO: 2)
H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-
1 2 3 4 5 6 7 8 9 10
Lys-Pro-Val
11 12 13
or a fragment, complex, aggregate, or analog thereof, or any combination thereof;
a ACTH1-24 peptide having the formula:
(SEQ ID NO: 3)
H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-
1 2 3 4 5 6 7 8 9 10
Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-
11 12 13 14 15 16 17 18 19 20
Lys-Val-Tyr-Pro
21 22 23 24
or a fragment, complex, aggregate, or analog thereof, or any combination thereof;
a ACTH1-17 peptide having the formula:
(SEQ ID NO: 4)
H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-
1 2 3 4 5 6 7 8 9 10
Lys-Pro-Val-Gly-Lys-Lys-Arg-
11 12 13 14 15 16 17
or a fragment, complex, aggregate, or analog thereof, or any combination thereof;
a ACTH4-10 peptide of formula:
(SEQ ID NO: 5)
Met-Glu-His-Phe-Arg-Trp-Gly
4 5 6 7 8 9 10
or a fragment, complex, aggregate, or analog thereof, or any combination thereof;
a ACTH4-9 peptide analog of formula:
(SEQ ID NO: 6)
Met-Glu-His-Phe-D-Lys-Phe-OH
or a fragment, complex, aggregate, or analog thereof, or any combination thereof;
a fragment of formula:
(SEQ ID NO: 7)
Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-
Pro-Val
or a fragment, complex, aggregate, or analog thereof, or any combination thereof;
a fragment of formula:
(SEQ ID NO: 8)
H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-
Pro-Val
or a fragment, complex, aggregate, or analog thereof, or any combination thereof; or
a fragment of formula:
(SEQ ID NO: 9)
D-Ala-Gln-Tyr-Phe-Arg-Trp-Gly-NH2
or a fragment, complex, aggregate, or analog thereof, or any combination thereof.

### Claim at position 11

11-21. (canceled)

### Claim 22 (depends on 1)

The method of claim 1, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered intramuscularly.

### Claim 23 (depends on 1)

The method of claim 1, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is administered subcutaneously.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

The method of claim 1, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a porcine ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.

### Claim 26 (depends on 1)

The method of claim 1, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a human ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.

### Claim 27 (depends on 1)

The method of claim 1, wherein the ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof, is a recombinant ACTH peptide or fragment, analog, complex or aggregate thereof, or any combination thereof.
The method of claim 1, further comprising administration of a second therapeutic agent selected from riluzole, ceftriaxone, methylcobalamine, Aeolus 10150, edaravone, hepatocyte growth factor (HGF), insulin growth factor (IGF), Atorvastatin, Lithium carbonate, Avanier 07-ACR-123 (Zenvia®), SB-509, Talampanel, Thalidomide, Arimoclomol, Olanzapine, KNS-760704, memantine, tamoxifen, ONO-2506PO, MCI-186, pioglitazone, ALS-357, creatine monohydrate, TCH346, Botulinum toxin type B, tauroursodeoxycholic acid, Dronabinol, coenzyme Q10, YAM80, Olesoxime, escitalopram (Lexapro®), sodium phenylbutyrate, ISIS 333611, granulocyte stimulating factor, neuronal growth factor (NGF), brain-derived neutrophic factor (BDNF), neutrophin 3 (NT3), basic fibroblast growth factor (bFGF), R(+) pramipexole dihydrochloride monohydrate, Sodium Valproate, AVP-923, sNN0029, Antithymocyte globulin, cyclosporin, corticosteroids, modafinil, or anti-CD40L, wherein the second therapeutic agent is administered sequentially or simultaneously.
